• 제목/요약/키워드: Adjuvant chemotherapy

검색결과 521건 처리시간 0.034초

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy with or without Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: Meta-analysis of 1,096 Patients from 11 Randomized Controlled Trials

  • Liang, Zhong-Guo;Zhu, Xiao-Dong;Tan, Ai-Hua;Jiang, Yan-Ming;Qu, Song;Su, Fang;Xu, Guo-Zeng
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권1호
    • /
    • pp.515-521
    • /
    • 2013
  • Purpose: To evaluate the efficacy and toxicity of induction chemotherapy followed by concurrent chemoradiotherapy (the treatment group) versus concurrent chemoradiotherapy with or without adjuvant chemotherapy (the control group) for locoregionally advanced nasopharyngeal carcinoma. Methods: The search strategy included Pubmed, Embase, the Cochrane Library, China National Knowledge Internet Web, Chinese Biomedical Database and Wanfang Database. We also searched reference lists of articles and the volumes of abstracts of scientific meetings. All randomized controlled trials were included for a meta-analysis performed with RevMan 5.1.0. The Grading of Recommendations Assessment, Development, and Evaluation system (GRADE) was used to rate the level of evidence. Results: Eleven studies were included. Risk ratios of 0.99 (95%CI 0.72-1.36), 0.37 (95%CI 0.20-0.69), 1.08 (95%CI 0.84-1.38), 0.98 (95%CI 0.75-1.27) were observed for 3 years overall survival, 3 years progression-free survival, 2 years loco-regional failure-free survival and 2 years distant metastasis failure-free survival. There were no treatment-related deaths in either group in the 11 studies. Risk ratios of 1.90 (95%CI 1.24-2.92), 2.67 (95%CI 0.64-11.1), 1.04 (95%CI 0.79-1.37), 0.98 (95%CI 0.27-3.52) were found for grade 3-4 leukopenia, grade 3-4 thrombocytopenia, grade 3-4 mucous membrane, and grade 3-4 hepatic hematologic and gastrointestinal toxicity, the most significant toxicities for patients. Conclusion: Compared with the control group, induction chemotherapy followed by concurrent chemoradiotherapy was well tolerated but could not significantly improve prognosis in terms of overall survival, loco-regional failure-free survival or distant metastasis failure-free survival.

Survival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey

  • Cokmert, Suna;Ellidokuz, Hulya;Demir, Lutfiye;Fuzun, Mehmet;Astarcioglu, Ibrahim;Aslan, Deniz;Yilmaz, Ugur;Oztop, Ilhan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권13호
    • /
    • pp.5195-5200
    • /
    • 2014
  • Background: The purpose of this study was to analyze our series of liver resections for metastatic colorectal carcinoma (mCRC) to determine prognostic factors affecting survival and to evaluate the potential roles of neoadjuvant or adjuvant chemotherapy. Materials and Methods: Ninety-nine patients who underwent metastasectomy for liver metastases due to colorectal cancer at the Department of Medical Oncology, 9 Eylul University Hospital between 1996 and 2010 were evaluated in this study. The patients were followed through July 2013. Demographic, perioperative, laboratory, radiological and chemotherapy as well as survival data were obtained by retrospective chart review. Results: In 47 (47.5%) patients, liver metastases were unresectable at initial evaluation; the remaining 52 (52.5%) patients exhibited resectable liver metastases. Simultaneous hepatic resection was applied to 52 (35.4%) patients with synchronous metastasis, whereas 5 (64.5%) patients underwent hepatic resection after neoadjuvant chemotherapy. Forty-two patients with metachronous metastasis underwent hepatic resection following neoadjuvant chemotherapy. R0 resection was obtained in 79 (79.8%) patients. A second hepatectomy was performed in 22 (23.2%) patients. Adjuvant chemotherapy was given to 85 (85.9%) patients after metastasectomy. The median disease-free and overall survivals after initial metastasectomy were 12 and 37 months, respectively, the 1-year, 3-year and 5-year disease-free survival (DFS) and overall survival (OS) rates being 46.5%, 24.3% and 17.9%and 92.3%, 59.0% and 39.0%, respectively. On multivariate analysis, the primary tumor site, tumor differentiation, resection margin and DFS were independent factors predicting better overall survival. Conclusions: In selected cases, hepatic metastasectomy for mCRC to the liver can result in long-term survival. Neoadjuvant chemotherapy did not exert a positive effect on DFS or OS. Adjuvant chemotherapy also did not appear to impact DFS and OS.

수술 후 Cisplatin을 투여받는 위암 환자의 구강영양섭취 실태 분석 (The Longitudinal Study on the Calorie and Protein Intakes and Food Choices in Gastrectomy Patients who Receiving Adjuvant Chemotherapy)

  • 전명희;왕수경
    • 대한간호학회지
    • /
    • 제32권2호
    • /
    • pp.206-219
    • /
    • 2002
  • This study was conducted to investigate nutrient and food choices in gastric cancer patients receiving Cisplatin after surgery. Ten patients were followed from the fist day of the first cycle to the last date of the 6th the cycle of the chemotherapy. The subjects kept daily self record of dietary intake and the period of nausea/vomiting during 6 cycles. Using Computer Aided Nutritional Analysis Program, the degree of Calorie, carbohydrate, protein, fat and fluid intakes according the chemotherapy period. The reseacher developed food intake rating scale, and then three dietitians analysed the oral intakes according to the type of foods. As the results of this study, during the chemotherapy cancer patients are intakes much fewer calorie, protein and fluids than recommended dietary allowance. Oral intake was worsen as treatment proceed. During the chemotherapy periods most of the patients choose fruits, vegitables, steam rice, porridge, yogurt and the beam soup to overcome nausea and vomiting. In order to promote oral intake for chemotherapy patients, the researcher strongly suggest that indiviual food preform should be considered.

Is conservative treatment (enucleation using modified Carnoy's solution) of odontogenic keratocyst in the maxilla good prognosis?

  • Woo Young Jeon;Jung Ho Park;Jeong-Kui Ku;Jin-A Baek;Seung-O Ko
    • Journal of the Korean Association of Oral and Maxillofacial Surgeons
    • /
    • 제49권5호
    • /
    • pp.287-291
    • /
    • 2023
  • Odontogenic keratocysts (OKCs) located in the maxillae have rarely been reported in the literature. Standard treatment modalities for OKC range from marsupialization to marginal resection. However, most of the studies on OKC treatment have been related to mandibular OKCs. The anatomical structure and loose bone density of the maxillae and the empty space of the maxillary sinus could allow rapid growth of a lesion and the ability to tolerate tumor occupancy in the entire maxilla within a short period of time. Therefore, OKCs of the maxillae require more aggressive surgery, suchas resection. As an alternative, this report introduces a modified Carnoy's solution, a strong acid, as an adjuvant chemotherapy after cyst enucleation. This report describes the clinical outcomes of enucleation using a modified Carnoy's solution in patients with large OKCs on the posterior maxillae. In three cases, application of a modified Carnoy's solution had few side effects or morbidity. Each patient was followed for four to six years, and none showed any signs of recurrence. In conclusion, adjuvant treatment with a modified Carnoy's solution can be considered a treatment option capable of reducing the recurrence rate of OKC in the maxillae.

Taxane-Based Regimens as Adjuvant Treatment for Breast Cancer: a Retrospective Study in Egyptian Cancer Patients

  • Azim, Hamdy Abdel;Abdal-Kader, Yasser Salah el din;Mousa, Mohamed Mahmoud;Malek, Raafat Abdel;Abdalmassih, Michael Kheir;Ibrahim, Noha Yehia
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권1호
    • /
    • pp.65-69
    • /
    • 2015
  • Background: To evaluate the impact of adding taxanes to anthracycline-based regimens in the adjuvant setting in localized young female breast cancer patients on the overall survival (OS) and the disease free survival (DFS). Materials and Methods: This retrospective study included all female breast cancer patients who were candidates for adjuvant chemotherapy presenting to Kasr Al Ainy centre of clinical oncology and Cairo oncology centre (Cairo Cure) in the period from January 2005 till December 2010. Results: Our study included 865 patients, 732 of whom received anthracycline based regimens and 133 taxane based regimens. The mean age of patients was 39 years. After a median follow up of 50 months the median DFS was 48.4 months. Survival analysis indicated that the tumor size (>5cm vs. <5cm) p=0.001), nodal involvement (Yes vs. No) p=0.0001) and pathology (invasive lobular vs. ductal) p=0.048) affected DFS. As regards hormonal status, ER, PR and HER 2neu positive patients had longer DFS (p=0.001, 0.003, 0.106). On multivariate analysis DFS was affected by tumor size and lymph node involvement (p=0.014, 0.007). Subgroup analysis showed improvement in arms treated with taxanes in terms of DFS with positive Her2neu, ER and PR, but this was not statistically significant. Conclusions: Adding adjuvant taxanes to anthracyclines is beneficial for treatment of localized breast cancer among all subgroups, especially higher risk groups. The type of adjuvant chemotherapy regimens and tumor characteristics have direct effects on DFS.

종골에 발생한 골육종 - 1예 보고 - (Osteosarcoma of the Calcaneus - A Case Report -)

  • 전영수;정남수;이진열
    • 대한골관절종양학회지
    • /
    • 제11권2호
    • /
    • pp.204-207
    • /
    • 2005
  • 골육종은 슬관절 주위에 호발하며 족부에 발생하는 경우는 흔하지 않다. 20세 남자 환자가 수개월간 지속된 좌측 종골 부위의 통증으로 내원하였으며 종골의 골육종으로 진단하여 슬하부 절단술 및 술 후 화학요법을 시행하였다. 이에 저자들은 종골에 발생한 골육종 1례를 경험하였기에 이를 문헌고찰과 함께 보고하는 바이다.

  • PDF

폐내의 흉막폐아세포종 (Pleuropulmonary Blastoma in Lung)

  • 박일;이응배
    • Journal of Chest Surgery
    • /
    • 제39권9호
    • /
    • pp.722-724
    • /
    • 2006
  • 흉막폐아세포종은 소아에서 발생하는 아주 드문 흉강 내 원발성 종양으로 폐아세포종과는 다른 병리학적 소견을 가진다. 수술적 완전 절제가 우선적인 치료법이며, 빠른 진행 및 전이를 보이기 때문에 신보조항암요법, 보조항암요법 등의 다각적인 방법을 고려하여야 한다. 저자들은 수술적 절제 및 보조항암요법으로 치료한 흉막폐아세포종 1예를 보고한다.

Novel Directions in Adjuvant Chemotherapy for Early Stage Epithelial Ovarian Cancer

  • Sakarya, Derya Kilic;Yetimalar, M Hakan;Ozbasar, Demir
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권10호
    • /
    • pp.4157-4160
    • /
    • 2015
  • Treatment of early stage ovarian cancer remains controversial despite advances in chemotherapeutic options. Over the past 30 years, molecular and clinicopathologic studies accelerated and treatment of ovarian cancer has undoubtedly improved although there is a debate as to whether this impacts outcome or not. More recently, the introduction of targeted therapy started a new era. Probably it is because early stage disease comprises a small portion of the epithelial ovarian cancer, studies have mostly ignored this group and still there is no clear consensus regarding systemic treatment of early-stage lesions. However this group of patients has the best chance of cure. In this review, we focus on current developments in the treatment of early stage ovarian cancer and query the options.

종격동에 발생한 거대 미성숙기형종 -1례 보고- (Huge Immature Teratoma of Mediastinum - A case report -)

  • 강재걸
    • Journal of Chest Surgery
    • /
    • 제22권5호
    • /
    • pp.867-872
    • /
    • 1989
  • Primary mediastinal immature teratoma is a rare germinal tumor which includes various elements of mature teratoma, choriocarcinoma, yolk sac carcinoma, embryonal carcinoma, and seminoma in some proportions. The tumor is virtually restricted to young man and the response to surgery and radiotherapy are poor. Recently, we experienced a case of primary mediastinal immature teratoma with elevated serum [-HCG and [-fetoprotein in 18 years old man. The well-encapsulated mass, weighing 4.5 kg, was completely resected and then adjuvant combination chemotherapy was tried with Vincristine, Bleomycin, and Cisplatin. Radical excision of tumor and adjuvant chemotherapy would appear to produce better result than have been reported in other cases. The postoperative course was uneventful and the tumor markers were returned to normal range.

  • PDF

Comparison of International Guidelines on the Accompanying Therapy for Advanced Gastric Cancer: Reasons for the Differences

  • Bauer, Katrin;Schroeder, Marcel;Porzsolt, Franz;Henne-Bruns, Doris
    • Journal of Gastric Cancer
    • /
    • 제15권1호
    • /
    • pp.10-18
    • /
    • 2015
  • The purpose of this study was to determine if international guidelines differ in their recommendations concerning additive therapy for advanced, but potentially curable, gastric cancer. A systematic search of the English and German literature was conducted in the databases Medline, Cochrane Database, Embase, and PubMed. The search terms used were 'guidelines gastric cancer,' 'guidelines stomach cancer,' and 'Leitlinien Magenkarzinom.' Six different guidelines published after January 1, 2010, in which the tumors were classified according to the seventh edition of the TNM system (2010), were identified. Although the examined guidelines were based on the same study results, their recommendations concerning accompanying therapy for gastric cancer differ considerably. While perioperative chemotherapy is recommended in Germany, Great Britain, and large parts of Europe, postoperative adjuvant radiochemotherapy or perioperative chemotherapy is recommended in the USA and Canada. In Japan, postoperative adjuvant chemotherapy is recommended. The results of identical studies were interpreted differently in different countries. Since considerable effort is required for each country to separately test relevant studies for their validity and suitability, an international cooperation could simplify the creation of a common basis for guidelines and contribute to improved comparability of international guidelines.